Immatics (IMTX)
(Delayed Data from NSDQ)
$6.18 USD
-0.14 (-2.22%)
Updated Aug 8, 2025 04:00 PM ET
After-Market: $6.30 +0.12 (1.94%) 7:58 PM ET
3-Hold of 5 3
D Value F Growth C Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
Currently, Immatics N.V. has a PEG ratio of 6.39 compared to the Medical - Biomedical and Genetics industry's PEG ratio of 1.43.
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
IMTX 6.18 -0.14(-2.22%)
Will IMTX be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for IMTX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for IMTX
Dynavax Technologies (DVAX) Q2 Earnings and Revenues Beat Estimates
Does Immatics (IMTX) Have the Potential to Rally 174.54% as Wall Street Analysts Expect?
IMTX: What are Zacks experts saying now?
Zacks Private Portfolio Services
ImmunityBio (IBRX) Reports Q1 Loss, Tops Revenue Estimates
Cardiff Oncology (CRDF) Reports Q1 Loss, Lags Revenue Estimates
Day One Biopharmaceuticals, Inc. (DAWN) Reports Q1 Loss, Tops Revenue Estimates
Other News for IMTX
IMTX Makes Bullish Cross Above Critical Moving Average
Iovance Biotherapeutics: ASCO Update, Competitor Data And The Road Ahead
Immatics N.V. Shareholders Approve Key Resolutions at June 2025 AGM
Tracking Baker Brothers Portfolio - Q1 2025 Update
Immatics: Taking Off On A PRAME Rocketship